Pérez‐Rangel 2017.

Methods	Randomized clinical trial
Participants	33 persistent egg‐allergic children, 5 years to 18 years old, with egg allergy diagnosis based on the presence of IgE‐ mediated symptoms, positive skin prick test (SPT) (≥ 3 mm) and/or specific IgE (sIgE) levels ≥ 0.7 kU/L or higher for whole egg, egg white, ovalbumin (OVA) and/or ovomucoid (OVM), and a positive double‐blind placebo‐controlled food challenge (DBPCFC) to dehydrated egg white at enrolment.
Interventions	A consecutive 5‐day build‐up phase was designed, starting at the highest tolerated single dose in the baseline egg DBPCFC. The build‐up phase target dose was 3,600 mg of dehydrated egg white (approximately 2808 mg of egg white protein). A cumulative dose of 5400 mg of dehydrated egg white (approximately 4212 mg protein) was administered on the last day. The maintenance phase consisted of eating 1 undercooked egg (undercooked fried egg, scrambled egg, or omelet) every 48 hours. In addition, the participants could freely take any other egg‐containing foodstuffs. Control group: egg avoidance diet during 5 months
Outcomes	The primary study outcome was the efficacy to induce desensitization to egg after 5 months of treatment. Desensitization was defined as the participant's ability to eat 1 undercooked egg with no or mild adverse events. Secondary objectives were: To evaluate the safety; To assess potential individual, single predictors for development of more than 2 adverse events; To detect immunologic changes linked to the clinical parameters.
Vested interest	Quote: "Authors have nothing to disclose."
Notes	The study was part of a research project supported in part by the Research Prize Merck Serono 2012 from the Salud 2000 Foundation and by a grant from ALK‐Abelló Laboratories. Additional data was received from the study authors (Ibanez Sandin MD 2017 [pers comm])
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were assigned to groups using a computer‐generated randomization table.
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unblinded intervention
Blinding of outcome assessment (detection bias) All outcomes	High risk	Unblinded intervention
Incomplete outcome data (attrition bias) All outcomes	Low risk	All outcomes accounted for and low level of attrition bias
Selective reporting (reporting bias)	Unclear risk	Study protocol not available